All Releases
 |
Manhattan Pharmaceuticals Announces Private Placement Final Close at $3.0 Million
Apr 14, 2010
|
8.6 KB |
|
| |
NEW YORK, Apr 14, 2010 (GlobeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced the final close of its private placement in which it sold approximately 121 units, including the conversion of approximately $400,000 of existing debt into 17 units, for an aggregate of $3,029,386 of its common stock and wa...
|
|
Manhattan Pharmaceuticals Completes Merger Transaction With Ariston Pharmaceuticals
Mar 12, 2010
|
12.5 KB |
|
| |
NEW YORK, Mar 12, 2010 (GlobeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced it has entered into a definitive agreement and plan of merger and completed the merger transaction with Ariston Pharmaceuticals, Inc., a privately-held, specialty pharmaceutical company. As a result of the merger, Ariston b...
|
|
Manhattan Pharmaceuticals Completes $2.5 Million Financing
Mar 4, 2010
|
8.9 KB |
|
| |
NEW YORK, Mar 4, 2010 (GlobeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced the private placement of $2,547,500 of its common stock and warrants to accredited investors. The Company intends to complete the previously announced merger transaction with Ariston Pharmaceuticals, Inc. within the next two...
|
|
Manhattan Pharmaceuticals Provides Corporate Update on Hedrin and Management Restructuring
Jun 18, 2009
|
9.6 KB |
|
| |
NEW YORK, Jun 18, 2009 (GlobeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today provided an update on its ongoing development programs. The Company also announced it has initiated a management restructuring that is intended to extend the Company's resources and allow it to continue working toward its near-term c...
|
|
Manhattan Pharmaceuticals Completes $1 Million Financing
Nov 25, 2008
|
9.3 KB |
|
| |
NEW YORK, Nov 25, 2008 (GlobeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced that it has completed the first closing of a private placement of secured debt and warrants to purchase shares of its common stock. Pursuant to the terms of the private placement, the Company can sell up to 500 units to acc...
|
|
Manhattan Pharmaceuticals Announces Results of Phase 2a Study of Topical PTH (1-34) for the Treatment of Psoriasis
Jul 31, 2008
|
9.4 KB |
|
| |
NEW YORK, Jul 31, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced top-line results from its Phase 2a clinical study of topical PTH (1-34) for the treatment of psoriasis. This multi-center, randomized, double-blind, vehicle-controlled, parallel group study was designed to assess the safety...
|
|
Manhattan Pharmaceuticals Announces Amendment of Joint Venture Deal With Nordic Biotech
Jun 13, 2008
|
11.3 KB |
|
| |
NEW YORK, Jun 13, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced that the FDA has directed Hedrin(tm), a novel, non-insecticide treatment for pediculosis (head lice), to the Center for Devices and Radiological Health (CDRH) division of the U.S. Food and Drug Administration (FDA) for revi...
|
|
Manhattan Pharmaceuticals to Present At Rodman & Renshaw 5th Annual Global Healthcare Conference
May 19, 2008
|
8.2 KB |
|
| |
NEW YORK, May 19, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced that Douglas Abel, president and chief executive officer, will present at the Rodman & Renshaw 5th Annual Global Healthcare Conference on Tuesday, May 20 at 7:40 AM EDT (1:40 PM local time). The conference is being held May...
|
|
Manhattan Pharmaceuticals Announces Completion of Enrollment in Phase 2a Study of Topical PTH (1-34) for Psoriasis
Apr 10, 2008
|
10.5 KB |
|
| |
NEW YORK, Apr 10, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) announced today that it has completed patient enrollment in its ongoing Phase 2a clinical study of Topical PTH (1-34). This randomized, double-blind, vehicle-controlled, parallel group study is designed to evaluate safety and preliminary e...
|
|
Manhattan Pharmaceuticals to Trade on OTCBB Under New Ticker Symbol MHAN
Mar 26, 2008
|
7.5 KB |
|
| |
NEW YORK, Mar 26, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced that it has obtained a new ticker symbol, "MHAN". Effective immediately the company's common stock will begin trading under the new ticker symbol on the OTC Bulletin Board(r) (OTCBB), the over-the-counter equity securities ...
|
|
Manhattan Pharmaceuticals Successfully Completes Pre-IND Meetings for Altoderm and Altolyn
Mar 6, 2008
|
10.6 KB |
|
| |
NEW YORK, Mar 6, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that it has concluded successful pre-IND (Investigational New Drug) meetings with the U.S. Food and Drug Administration (FDA) and may file IND applications for both Altoderm(tm) and Altolyn(tm). The company intends to develop ...
|
|
Manhattan Pharmaceuticals Announces Closing of Joint Venture With Nordic Biotech
Feb 27, 2008
|
11.1 KB |
|
| |
NEW YORK, Feb 27, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced the closing of its joint venture agreement with Nordic Biotech Venture Fund II K/S (Nordic) to develop and commercialize Hedrin(tm), the company's novel, non-insecticide treatment for head lice for the North American market. ...
|
|
Manhattan Pharmaceuticals to Voluntarily Withdraw Its American Stock Exchange Common Stock Listing
Feb 22, 2008
|
10.7 KB |
|
| |
NEW YORK, Feb 22, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that it has formally notified the American Stock Exchange ("AMEX") that it intends to voluntarily delist its common stock from AMEX. The company expects that the delisting will become effective within the next 25 calendar day...
|
|
Manhattan Pharmaceuticals to Present At the BIO CEO & Investor Conference 2008
Feb 8, 2008
|
7.7 KB |
|
| |
NEW YORK, Feb 8, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that Douglas Abel, president and chief executive officer, will present at the BIO CEO & Investor Conference 2008 on Tuesday, February 12, 2008 at 12:30 PM ET. The conference is being held at Waldorf Astoria Hotel in New York C...
|
|
Manhattan Pharmaceuticals Announces Joint Venture With Nordic Biotech for Lead Product Hedrin
Feb 5, 2008
|
10.5 KB |
|
| |
NEW YORK, Feb 5, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that it has entered into a joint venture agreement with Nordic Biotech Advisors ApS (Nordic) to develop and commercialize Hedrin™, the company's novel, non-insecticide treatment for head ...
|
|
Manhattan Pharmaceuticals Names Mary C. Spellman, M.D. as Head of Dermatology and Drug Development
Dec 27, 2007
|
8.8 KB |
|
| |
NEW YORK, Dec 27, 2007 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced the appointment of Mary C. Spellman, M.D. as its consultant Head of Dermatology and Drug Development. Dr. Spellman will oversee all aspects of clinical operations related to the development of Manhattan Pharmaceuticals' produ...
|
|
AMEX Accepts Manhattan Pharmaceuticals' Plan to Regain Compliance with Continued Listing Standards
Dec 10, 2007
|
7.3 KB |
|
| |
NEW YORK, Dec 10, 2007 (BUSINESS WIRE) -- Manhattan Pharmaceuticals, Inc. (AMEX: MHA) today announced that the American Stock Exchange (AMEX) has accepted the Company's plan to regain compliance with continued listing standards of AMEX. The Company's plan was submitted in response to a letter from AMEX which informed the Company that it was not in ...
|
|
Manhattan Pharmaceuticals Announces Positive Clinical Results for Hedrin in Treatment of Head Lice
Nov 28, 2007
|
11.0 KB |
|
| |
NEW YORK, Nov 28, 2007 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced the publication of positive clinical results for Hedrin(tm), the company's novel, non-insecticide product candidate for the treatment of head lice. These results appeared in the November issue of PLoS One, a leading internati...
|
|
Manhattan Pharmaceuticals to Present At Wall Street Analyst Forum
Nov 26, 2007
|
7.7 KB |
|
| |
NEW YORK, Nov 26, 2007 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that Douglas Abel, president and chief executive officer, will present at the Wall Street Analyst Forum on Wednesday, November 28, 2007, at 9:10 a.m. EST. The conference is being held at The Princeton Club in New York City.
...
|
|
Manhattan Pharmaceuticals to Present At Informed Investors Biotech/Pharma/Healthcare On-line Forum
Nov 12, 2007
|
7.7 KB |
|
| |
NEW YORK, Nov 12, 2007 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that Douglas Abel, president and chief executive officer, will present at the Informed Investors Biotech/Pharma/Healthcare On-line Forum on Tuesday, November 13, 2007 at 9:30 AM ET.
To access the audio webcast for this pr...
|
|
|
